AAAAAA

   
Results: 1-16 |
Results: 16
Sentinel lymph node biopsy for melanoma: How many radioactive nodes shouldbe removed?
Authors: McMasters, KM Reintgen, DS Ross, MI Wong, SL Gershenwald, JE Krag, DN Noyes, RD Viar, V Cerrito, PB Edwards, MJ
Citation: Km. Mcmasters et al., Sentinel lymph node biopsy for melanoma: How many radioactive nodes shouldbe removed?, ANN SURG O, 8(3), 2001, pp. 192-197
Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes
Authors: Porter, GA Abdalla, J Lu, MS Smith, S Montgomery, D Grimm, E Ross, MI Mansfield, PF Gershenwald, JE Lee, JE
Citation: Ga. Porter et al., Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes, ANN SURG O, 8(2), 2001, pp. 116-122
Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo
Authors: Gershenwald, JE Sumner, W Calderone, T Wang, Z Huang, SY Bar-Eli, M
Citation: Je. Gershenwald et al., Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo, ONCOGENE, 20(26), 2001, pp. 3363-3375
Sentinel lymph node biopsy for conjunctival melanoma
Authors: Esmaeli, B Eicher, S Popp, J Delpassand, E Prieto, VG Gershenwald, JE
Citation: B. Esmaeli et al., Sentinel lymph node biopsy for conjunctival melanoma, OPHTHAL PL, 17(6), 2001, pp. 436-442
Prognostic factors analysis of 17,600 melanoma patients: Validation of theAmerican Joint Committee on Cancer melanoma staging system
Authors: Balch, CM Soong, SJ Gershenwald, JE Thompson, JF Reintgen, DS Cascinelli, N Urist, M McMasters, KM Ross, MI Kirkwood, JM Atkins, MB Thompson, JA Coit, DG Byrd, D Desmond, R Zhang, YT Liu, PY Lyman, GH Morabito, A
Citation: Cm. Balch et al., Prognostic factors analysis of 17,600 melanoma patients: Validation of theAmerican Joint Committee on Cancer melanoma staging system, J CL ONCOL, 19(16), 2001, pp. 3622-3634
Final version of the American Joint Committee on Cancer staging system forcutaneous melanoma
Authors: Balch, CM Buzaid, AC Soong, SJ Atkins, MB Cascinelli, N Coit, DG Fleming, ID Gershenwald, JE Houghton, A Kirkwood, JM McMasters, KM Mihm, MF Morton, DL Reintgen, DS Ross, MI Sober, A Thompson, JA Thompson, JF
Citation: Cm. Balch et al., Final version of the American Joint Committee on Cancer staging system forcutaneous melanoma, J CL ONCOL, 19(16), 2001, pp. 3635-3648
Sentinel lymph node biopsy for melanoma: Controversy despite widespread agreement
Authors: McMasters, KM Reintgen, DS Ross, MI Gershenwald, JE Edwards, MJ Sober, A Fenske, N Glass, F Balch, CM Coit, DG
Citation: Km. Mcmasters et al., Sentinel lymph node biopsy for melanoma: Controversy despite widespread agreement, J CL ONCOL, 19(11), 2001, pp. 2851-2855
Patterns of regional and distant metastasis in patients with conjunctival melanoma - Experience at a cancer center over four decades
Authors: Esmaeli, B Wang, XM Youssef, A Gershenwald, JE
Citation: B. Esmaeli et al., Patterns of regional and distant metastasis in patients with conjunctival melanoma - Experience at a cancer center over four decades, OPHTHALMOL, 108(11), 2001, pp. 2101-2105
Significance of multiple nodal basin drainage in truncal melanoma patientsundergoing sentinel lymph node biopsy
Authors: Porter, GA Ross, MI Berman, RS Lee, JE Mansfield, PF Gershenwald, JE
Citation: Ga. Porter et al., Significance of multiple nodal basin drainage in truncal melanoma patientsundergoing sentinel lymph node biopsy, ANN SURG O, 7(4), 2000, pp. 256-261
Regional nodal basin control is not compromised by previous sentinel lymphnode biopsy in patients with melanoma
Authors: Gershenwald, JE Berman, RS Porter, G Mansfield, PF Lee, JE Ross, MI
Citation: Je. Gershenwald et al., Regional nodal basin control is not compromised by previous sentinel lymphnode biopsy in patients with melanoma, ANN SURG O, 7(3), 2000, pp. 226-231
Role for lymphatic mapping and sentinel lymph node biopsy in patients withthick (>= 4 mm) primary melanoma
Authors: Gershenwald, JE Mansfield, PF Lee, JE Ross, MI
Citation: Je. Gershenwald et al., Role for lymphatic mapping and sentinel lymph node biopsy in patients withthick (>= 4 mm) primary melanoma, ANN SURG O, 7(2), 2000, pp. 160-165
Classification and staging of melanoma
Authors: Gershenwald, JE Buzaid, AC Ross, MI
Citation: Je. Gershenwald et al., Classification and staging of melanoma, CLIN LAB M, 20(4), 2000, pp. 785
Clinical classification and staging
Authors: Gershenwald, JE Fischer, D Buzaid, AC
Citation: Je. Gershenwald et al., Clinical classification and staging, CLIN PLAST, 27(3), 2000, pp. 361
How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma?
Authors: Porter, GA Rose, MI Berman, RS Sumner, WE Lee, JE Mansfield, PF Gershenwald, JE
Citation: Ga. Porter et al., How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma?, SURGERY, 128(2), 2000, pp. 306-311
A new American Joint Committee on Cancer staging system for cutaneous melanoma
Authors: Balch, CM Buzaid, AC Atkins, MB Cascinelli, N Coit, DG Fleming, ID Houghton, A Kirkwood, JM Mihm, MF Morton, DL Reintgen, D Ross, MI Sober, A Soong, SJ Thompson, JA Thompson, JF Gershenwald, JE McMasters, KM
Citation: Cm. Balch et al., A new American Joint Committee on Cancer staging system for cutaneous melanoma, CANCER, 88(6), 2000, pp. 1484-1491
Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
Authors: Gershenwald, JE Thompson, W Mansfield, PF Lee, JE Colome, MI Tseng, CH Lee, JJ Balch, CM Reintgen, DS Ross, MI
Citation: Je. Gershenwald et al., Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients, J CL ONCOL, 17(3), 1999, pp. 976-983
Risultati: 1-16 |